Xbiotech (XBIT) closed at $1.88 on October 30, 2026, down 3.1% from the previous close, on volume of 50,320 shares (30-day average 70,269).
Data as of October 30, 2026.
30-Oct-2026
No headlines found.
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
Globe Newswire (Fri, 23-Oct 9:17 AM ET)
Globe Newswire (Mon, 19-Oct 9:00 AM ET)
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Xbiotech trades on the NASDAQ stock market under the symbol XBIT.
As of October 30, 2026, XBIT stock price declined to $1.88 with 50,320 million shares trading.
XBIT has a beta of 0.57, meaning it tends to be less sensitive to market movements. XBIT has a correlation of 0.05 to the broad based SPY ETF.
XBIT has a market cap of $57.31 million. This is considered a Micro Cap stock.
In the last 3 years, XBIT traded as high as $9.96 and as low as $1.80.
The top ETF exchange traded funds that XBIT belongs to (by Net Assets): VXF, IWC, BSVO, AVSC.
XBIT has underperformed the market in the last year with a price return of -21.7% while the SPY ETF gained +12.3%. XBIT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.1% and -11.3%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
XBIT support price is $1.87 and resistance is $2.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBIT shares will trade within this expected range on the day.
